Coming Of Age: Pharma’s Influencer Marketing Matures

Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.

social media
• Source: Shutterstock

In regulated sectors like pharmaceuticals, influencer marketing poses both challenges and opportunities. Companies must disseminate accurate and compliant information about health care products, leading to cautious approaches. However, as digital landscapes evolve and consumer behavior changes, the pharmaceutical industry is adapting its influencer marketing strategies. According to marketing software firm Traackr’s Impact 2024 report, 63% of shoppers say they are more likely to buy a product that is recommended to them by a social media influencer that they trust. This highlights the fact that an influencer need not be a celebrity, it is more important to consumers (and therefore patients) that they gain information from an influencer that is close to them in terms of lifestyle, values and priorities.

Novartis AG is just one of many large pharma companies embracing the power of influencer marketing. It has run...

More from Business Strategy

More from In Vivo

Rising leaders 2025: Aneesh Karatt-Vellatt On Maxion Therapeutics’ Antibody Revolution

 
• By 

Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By 

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.